Studies funded by the Rheumatology Research Foundation link bacteria that contributes to gum disease to increased risk of developing RA
Rheumatology Professionals, Patients Carry Important Messages to Capitol Hill
Attendees of the ACR’s Advocates for Arthritis conference last September shared their stories and encouraged Congressional lawmakers to support research funding for rheumatic diseases
Researchers Look for Therapeutic Clues to Sjögrens Syndrome in Neural Pathways
Beyond biologic agents, scientists study cytokines, chemokines, and the interface between inflammatory and neural/secretory pathways
Colchicine Effective for Acute Pericarditis
Patients with acute pericarditis who are treated with colchicine in combination with a traditional antiinflammatory therapy experience a significantly reduced rate of incessant or recurrent pericarditis. (posted Oct. 31)
Survey Highlights High Out-of-pocket Costs for RA Care
The “RA in America 2013″ survey estimates out-of-pocket cost for RA treatment at $1,000 to $5,000 per year. (posted Oct. 25)
Telomere Length Provides Insights into Cartilage Aging and Repair
Chondrocyte telomere length might play a role in the natural aging of cartilage, as well as the development and progression of OA. (posted Oct. 8, 2013)
Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia
A new study suggests that patients diagnosed with RA as well as dyslipidemia may benefit from more aggressive antirheumatic therapy. (posted Oct. 3, 2013)
Immunology Research Pioneers Receive Carol Nachman Prize
Rheumatologists Gerd R. Burmester, MD, of Berlin, and Michael B. Brenner, MD, of Boston, honored with prestigious international award
Interplay Between Physician Employment Agreements, Medical Staff Bylaws Should Not be Ignored
Doctors must consider and review bylaws of hospital medical staff privileges when entertaining employment with a hospital or private practice
EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
Guidelines give greater nod to use of combination conventional disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, leave monotherapy with methotrexate as acceptable first-line treatment
- « Previous Page
- 1
- …
- 228
- 229
- 230
- 231
- 232
- …
- 300
- Next Page »